2014 Conference Program

2014 WAFSF on Stem Cell Research and Regenerative Medicine
THE IMPACT OF REGENERATIVE MEDICINE 2014

Date: Thursday November 6 and Friday, November 7th, 2014
Location: Mission Bay Conference Center at UCSF, 1675 Owens Street, San Francisco, CA 94143
Organizer: Alliance Forum Foundation, USA (AFFUSA)
Tickets: General Registration: $800. For further inquiries or offers on special rates, email us at wafsf@allianceforum.org.

PROGRAM – DAY 1
Thursday, November 6, 2014

Master of Ceremonies
Elona Baum Esq.
 VP, Ass. General Counsel, Coherus BioSciences, Inc. (former General Counsel & Vice President of Business Development, California Institute for Regenerative Medicine, CIRM)

8:20–9:00 Conference Registration
9:00–9:10 Opening & Welcome Remarks: Mr. Isao “Steve” Matsuura, Conference Co-chair and Council Member, Alliance Forum Foundation and The Honorable Masato Watanabe, Consul General, Consulate General of Japan in San Francisco

THE LANDSCAPE OF STEM CELL RESEARCH AND REGENERATIVE MEDICINE
Session I
Regenerative Medicine 2014

Session Chair: Michael Werner

9:10–10:40 Opening Address:“The State of the Industry — Progress, Promise, and Challenges,” Michael Werner, Executive Director, Alliance for Regenerative Medicine (ARM)Presentations:

“My Journey Advocating for Stem Cell Research and Cures,” Roman Reed, President, Roman Reed Foundation, Chairman, The Alabama Institute of Medicine, President, Sacred Cell Research Partners

“A Nonprofit Biotech’s Role in Accelerating Cures through Stem Cell Research,” Susan L. Solomon, JD, CEO, New York Stem Cell Foundation

“Realizing the promise of stem cell research,” Arlene Chiu, PhD, Director, Office of New Research Initiatives, Beckman Research Institute, City of Hope

“Ten @ Ten & CIRM 2.0: How the Numbers Tell the Story,” Jonathan Thomas, PhD, JD, Chair, Governing Board of the CIRM (Independent Citizens Oversight Committee)

Yuzo Toda, Forum for Innovative Regenerative Medicine (FIRM)

Discussion moderated by Michael Werner:

Arlene Chiu, Susan L. Solomon, Jonathan Thomas, Yuzo Toda and Roman Reed

10:40-10:55 Coffee Break

Session II:
Business Perspectives on the Regenerative Medicine Space

Session Chair: Elona Baum

10:55-11:50 Panel Discussion: Elona Baum, Esq. (Moderator), VP, Ass. General Counsel, Coherus BioSciences, Inc. (formerly VP, General Counsel and Business Development, CIRM)

Rahul Aras, PhD President and Chief Executive Office, Juventas Therapeutics

Edward Lanphier President and CEO, Sangamo BioSciences Inc.

Jay Lee, PhD, Senior Director, Business Development, Medipost

Emile Nuwaysir, PhD, COO, Cellular Dynamics International)

11:50–12:10 Company Presentations:
ROHTO PHARMACEUTICAL CO. LTD., Katsuya Hisamichi, MD, Executive Officer
CELLULAR THERAPIES, MAXCYTE, INC., Madhusudan V. Peshwa, PhD, Executive Vice President
12:10–13:00 Complimentary Lunch in the Fisher Banquet Room

DAY 1
Afternoon: Thursday, November 6, 2014


Session III
Frontiers of Regenerative Medicine

Session Chair: Hiromitsu Nakauchi

13:00-14:15 Presentations:

“Cell Fiber Technology for Regenerative Medicine,” Shoji Takeuchi, PhD, Professor, The Biohybrid Systems Laboratory, The University of Tokyo

“Realization of iPSC-Organ Bud Transplantation Therapy,” Takanori Takebe, MD, Associate Professor, Department of Regenerative Medicine, Yokohama City University

“From Cells to Organs: Generation of Functional Organs from Pluripotent Stem Cells,” Hiromitsu Nakauchi, MD, PhD, Professor, Stanford University and The University of Tokyo
14:15–14:35 Company Presentations:
KURARAY CO. LTD.
CELL THERAPY, CUSTOM MANUFACTURING ORGANIZATION (CMO), LONZA WALKERSVILLE, INC., Don Paul Kovarcik, MBA, Business Development Manager, “From the Nobel Prize to the Clinic: One Step Closer to iPSC-based Therapies.”

FROM THE LABORATORY TO CLINICAL APPLICATION
Master of Ceremonies

Ms. Diane Dwyer, Reporter, NBC Bay Area News
A Special Presentation by Dr. Shinya Yamanaka, 2012 Nobel Laureate

14:35-14:45 Introduction: Robert Mahley, MD, PhD, Founder & President Emeritus, Professor of Pathology and Medicine, Gladstone Institutes
14:45–15:15 Keynote Speech: “Recent Progress in iPS Cell Research and Application,” Shinya Yamanaka, MD, PhD, Professor and Director of the Center for iPS Cell Research and Application (CiRA), Kyoto University; Senior Investigator, L.K. Whittier Foundation Investigator in Stem Cell Biology, Gladstone Institutes, Professor, Anatomy, University of California, San Francisco
15:15–15:30 Coffee Break

Session IV
From the Laboratory to Clinical Applications

Session Chair: Shinya Yamanaka

15:30–16:50 Presentations:

“iPS Cell Technologies: Significance and Applications to CNS Regeneration and Disease Research,” Hideyuki Okano, MD, PhD,Professor, Department of Physiology, Graduate School of Medicine, Keio University; Chairman, Graduate School of Medicine, Keio University

“Pre-Clinical Development of a Humanized Anti-CD47 Antibody Targeting AML Stem Cells,” Ravi Majeti, MD, PhD, Assistant Professor of Medicine (Hematology), Stanford University

“Cell Sheet Tissue Engineering for Clinical Applications,” Teruo Okano, PhD, The Japanese Society for Regenerative (JSRM) Medicine & Institute of Advanced Biomedical Engineering and Science, Tokyo Women’s Medical University

“Induction of Immunological Tolerance by T-Regulatory Cells: From Discovery to Clinical Application,” Maria-Grazia Roncarolo, MD, Co-director, Institute for Stem Cell Biology and Regenerative Medicine; George D. Smith Professor in Stem Cell and Regenerative Medicine; Chief of the Division of Pediatric Translational and Regenerative Medicine; Professor of pediatrics and of medicine (blood and marrow transplantation), Stanford University.

16:50–17:20 Discussion moderated by Ravi Majeti:Hideyuki Okano,, Teruo Okano, Maria-Grazia Roncarolo, Shinya Yamanaka and Paul Berg, PhD, Nobel Laureate, Director Emeritus Beckman Center and Professor Emeritus Biochemistry, Stanford University School of Medicine
17:20–17:30 Closing Remarks: George Hara, Chairman of the Board, Alliance Forum Foundation
17:30–19:00 Cocktail Reception in the Main Lobby (1st Floor)


PROGRAM – DAY 2
Morning: Friday, November 7, 2014


8:30–9:00 Complimentary Continental Breakfast

Master of Ceremonies
Yoriko Kishimoto, former Mayor of Palo Alto
Board director, Midpeninsula Regional Open Space District

9:00–9:10 Welcome: Susumu Kaminaga, Council Member, Alliance Forum Foundation and Yoshio Yamawaki, Deputy Director-General, Research Promotion Bureau, Ministry of Education, Culture, Sports, Science and Technology (MEXT)

DEVELOPMENTS IN REGENERATIVE MEDICINE, 2014
Session V: Eye and Retina

Session Chair: Henry Klassen

09:05–10:50 Special Speech:

“Transplantation of iPS-Derived Retinal Cells,” Masayo Takahashi, MD, PhD, Project Leader, Laboratory for Retinal Regeneration Research, RIKEN

Presentations:

“ES-derived RPE for the Treatment of AMD: The California Project to Cure Blindness,” David Hinton, MD, Gavin S. Herbert Professor in Retinal Research, Professor of Pathology, Neurological Surgery and Ophthalmology, Keck School of Medicine, University of Southern California

“Human Neural Stem Cells: Potential Application for Dry Age-Related Macular Degeneration,” Ann Tsukamoto, PhD, Executive Vice President, Scientific and Strategic Alliances, StemCells, Inc.

“Retinal Progenitor Cells for Treatment of Retinitis Pigmentosa,” Henry Klassen, MD, PhD,Associate Professor and Director, Stem Cell & Retinal Regeneration Program, Ophthalmology, School of Medicine, University of California, Irvine
10:50–11:05 Coffee Break

Master of Ceremonies
Tasha Yorozu, Managing Attorney, Yorozu Law Group. P.C.

11:05-11:20 Company Showcase:
“What It Takes to Bring the World’s First iPSC-based Replacement Therapy for Patients Globally,” Hardy T S Kagimoto, MD, President and CEO, HEALIOS KK

Session VI
Cardiovascular

Session Chair: Deepak Srivastava

11:20-12:30 Special Speech (20 mins.): “Regenerative Therapy for Severe Heart Failure Patients,” Yoshiki Sawa, MD, PhD, Division of Medicine Graduate School of Medicine, Osaka University
Presentations:

“Cardiac iPSCs for Disease Modeling and Drug Discovery,” Joseph C. Wu, MD, PhD, Director, Stanford Cardiovascular Institute, Professor, Dept of Medicine/Cardiology & Radiology, Stanford University School of Medicine

“Cardiac Reprogramming for Regenerative Medicine,” Deepak Srivastava, MD, Director and Senior Investigator, Gladstone Institute of Cardiovascular Disease; Director, Roddenberry Center for Stem Cell Biology and Medicine; Professor, Departments of Pediatrics and Biochemistry & Biophysics, University of California, San Francisco; Wilma and Adeline Pirag Distinguished Professor in Pediatric Developmental Cardiology, University of California, San Francisco
12:30–13:20 Complimentary Lunch in Fisher Banquet Room

DAY 2
Afternoon: Friday, November 7, 2014


A PROMISE OF LIFE SCIENCE REVOLUTION

13:20–13:25 Introduction of Mahendra Rao: Ken-ichi Arai, MD, PhD, Professor Emeritus and former Dean of the Institute of Medical Science, The University of Tokyo (IMSUT); Founder & Chairman, SBI Biotech, Co., Ltd.
13:25–13:55 Keynote Speech: “Moving iPSC to the Clinic–Issues and Solutions,” Mahendra Rao, MD PhD, Vice-president of Regenerative Medicine, New York Stem Cell Foundation and former Director, NIH Center for Regenerative Medicine

Session VII
Stem Cells and Translational Research

Session Chair: Ken’ichi Arai

13:55–14:45 Remarks:
Ken-ichi Arai, MD, PhD, Professor Emeritus and former Dean of the Institute of Medical Science, The University of Tokyo (IMSUT); Founder & Chairman, SBI Biotech, Co., Ltd.
Presentations:

Shigetaka Asano, MD, PhD, Professor Emeritus, School of Science and Engineering, Waseda University, The Institute of Medical Science, The Tokyo University (IMSUT)

Leonore A. Herzenberg, PhD, Professor, Genetics Department, Stanford University

Tony Lee, PhD, CEO and Managing Director, MEDIPOST America, Inc.

14:45-15:05 Company Presentations:
SANBIO INC., Keita Mori, MBA, Co-CEO, Chairman, Co-founder
NIHON UNISYS, INC., Masao Watase, Business Development Manager
15:05–15:20 Coffee Break
15:20-15:40 Company Presentations:
MIKIKAI MEDICAL CORPORATION, SUN FIELD CLINIC, Nobuo Kubo, MD, PhD

Session VIII
The Future of Regenerative Medicine: Five, Ten Years from Now

Session Chair: Regis Kelly

15:40–16:50 Presentations:
“The Future Promise of Insights and Applications Provided by Studying Regenerative Medicine,” Thea Tlsty, PhD, Director of the Center for Translational Research in the Molecular Genetics of Cancer, University of California, San Francisco
“Molecular Elucidation and Engineering of Stem Cell Microenvironments for Therapeutic Application,” David Schaffer, PhD, Director of Stem Cell Center, University of California, Berkeley

“The Future of Regenerative Medicine,” Regis Kelly, PhD, Director, QB3, University of California, San Francisco
16:50–17:10 Concluding Remarks: George Hara, Chairman, Alliance Forum Foundation
17:10–18:00 Cocktail Reception

 

Please visit this link to learn about business opportunities available at this year’s Conference.

Stem cell research is quickly developing today, as are the possibilities of its applications, which range from disease research and drug development to experimental growth of entirely new organs. Stem-cell technologies harbor the potential for a paradigm shift in regenerative medicine, healthcare, and society at large. However, many challenges still need to be overcome before we will be able to reap the benefits.

  • discuss the exciting possibilities of stem-cell applications and how they will affect our future;
  • examine the accompanying research and business and regulatory hurdles;
  • facilitate the establishment of networks of researchers, entrepreneurs, large corporations, policy-makers, and patient advocates for the development of regenerative medicine as a sustainable industry; and
  • encourage the building of a new business environment where “public interest” becomes the guiding standard and where successful businesses reallocate a portion of their profit to basic research, as well as to other stakeholders in the new ecosystem.

The Conference will be lead by internationally recognized figures working primarily in the Bay Area and Japan. The Conference will also bring together venture capital and businesses already involved in, or expected to play a significant role in, the future development of regenerative medicine as a new health delivery system. We also look forward to the participation of regulators, rare disease philanthropists, and patient advocates so that a diverse range of stakeholders will be represented.

With its sessions, pre-session workshops, and business presentations, the Conference will provide the best opportunity to meet with people from the Bay Area and Japan, share views and knowledge, build new relationships, and explore business opportunities!